Master Regulator Protein Reprogramming for Multipotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for identifying functionally relevant genes in somatic cell reprogramming to pluripotency rely heavily on differential expression analysis, making it difficult to distinguish causally relevant driver-genes from passenger-genes, thus hindering the clear differentiation of mechanistic drivers of reprogramming events.
Innovation Solution
A method involving protein transduction or other means to deliver Master Regulator (MR) proteins such as BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, and FLI1 into somatic cells, using techniques like protein transduction, viral delivery, or mRNA delivery, to reprogram somatic cells into multipotent stem cells, leveraging VIPER analysis to identify and validate these proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If differential expression analysis is used to identify functionally relevant genes in somatic cell reprogramming, then gene identification can be performed, but it is difficult to distinguish causally relevant driver-genes from passenger-genes
Solution Approach 1:
The patent uses cell-to-cell fusion as an intermediary approach to study reprogramming. By fusing somatic cells with embryonic stem cells, the patent creates a hybrid system where master regulator proteins from ESCs can be directly delivered into somatic nuclei, enabling precise identification of causal genes rather than relying on differential expression analysis alone
Solution Approach 2:
The patent replaces the indirect differential expression analysis method with a direct protein delivery mechanism through cell fusion. This substitution allows direct observation of causal relationships by introducing specific master regulator proteins into somatic cells and observing the reprogramming effects, rather than inferring causality from expression changes
2Reliability
If cell-to-cell fusion approaches are used to study reprogramming events, then early reprogramming events can be elucidated, but the complexity of identifying causally relevant genes increases
Solution Approach 1:
The patent extracts and isolates specific master regulator proteins from embryonic stem cells and delivers them directly into somatic cells through cell fusion. This extraction approach allows individual master regulators to be studied independently, simplifying the identification of causally relevant genes while maintaining reliable detection of reprogramming events
Solution Approach 2:
The patent segments the complex reprogramming process by focusing on specific master regulator proteins as discrete functional units. By studying individual master regulators (such as BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, and FLI1) separately through cell fusion, the patent reduces the complexity of gene identification while maintaining reliable detection of reprogramming events
Data Source
AI summary
The method of generating multipotent stem cells is a method for producing and/or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1â/â murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.